Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Numerion Labs

Biotech & Life Sciences · San Francisco, United States · Founded 2012

Atomwise is a startup that operates in the pharmaceutical industry, leveraging artificial intelligence (AI) to revolutionize drug discovery. The company's primary offering is an AI engine that uses machine learning and convolutional neural networks to sift through vast chemical libraries. This technology enables Atomwise to identify new small molecule medicines more efficiently and effectively than traditional methods. The company's clients are primarily in the healthcare and pharmaceutical sectors, who are looking for more efficient ways to discover new drugs. Atomwise's business model is based on developing and co-developing pipeline assets, which are then backed by investors. This means that the company makes money by creating and improving medicines, and then selling these discoveries to pharmaceutical companies or healthcare providers. Atomwise's unique selling point is its combination of AI and machine learning, which allows it to create better medicines faster. This not only reduces the time and cost associated with drug discovery, but also has the potential to improve patient outcomes by delivering more effective treatments. In conclusion, Atomwise is a forward-thinking startup that is using AI to disrupt the traditional drug discovery process. Its innovative approach has the potential to make a significant impact on the pharmaceutical industry and improve the lives of patients worldwide. Keywords: Atomwise, Startup, Artificial Intelligence, Machine Learning, Drug Discovery, Pharmaceutical Industry, Healthcare, Convolutional Neural Networks, Small Molecule Medicines, Pipeline Assets.

Valuation
$100–500M
Latest valuation · 2020
Unlock exact value
Headcount
<100
Current team size
Unlock exact value
Total funding Pre-IPO
$100–500M
Unlock exact value

Investors

18 investors on Numerion Labs's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 10 investors entered at this stage
Grand Challenges Canada
Y Combinator
Khosla Ventures
David E. Weekly
Draper Associates
Farzad (Zod) Nazem
Mission and Market
OS Fund
AME Cloud Ventures
Bill & Melinda Gates Foundation
Series A 8 investors entered at this stage
Monsanto
Dolby Family Ventures
DFJ Growth
B Capital
Baidu Ventures
Sanabil
Tencent
DCVC

Global footprint

Where Numerion Labs has talent and traffic

Workforce by country
🇺🇸 United States · San Francisco HQ
Book a demo for the full country breakdown

Talent graph

The shape of Numerion Labs's talent

Dealroom maps Numerion Labs's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

17 team members profilednamed & role-tagged by Dealroom
20 employeestotal headcount
1 executives & foundersidentified by name
DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Numerion Labs's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about Numerion Labs

An AI-synthesized read of the highest-engagement posts about Numerion Labs on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Numerion Labs on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.